rewrite this title First Drug of Its Kind Developed to Repair DNA Damage | Metaverse Planet

Scientists have developed an experimental drug capable of repairing DNA and healing tissue damage. Named TY1, this drug stands out as the first prototype of a new class of drugs aimed at correcting tissues damaged in heart attacks, inflammatory diseases, and other conditions.

First Example of a New Class of Drugs TY1 is a laboratory-produced version of an RNA molecule naturally found in the body. The research team demonstrated that TY1 increases the activity of the TREX1 gene, allowing immune cells to clear damaged DNA and contribute to tissue repair.

The development process of TY1 spans over twenty years. The starting point of the invention dates back to the isolation of progenitor cells from human heart tissue in a laboratory at Johns Hopkins University. Progenitor cells, which share properties similar to stem cells, can create new healthy tissue in a more focused manner and contribute to heart regeneration.

In studies conducted at Cedars-Sinai, Ahmed Ibrahim discovered that heart progenitor cells release small vesicles filled with RNA molecules, known as exosomes. The RNAs in these vesicles guide the repair and regeneration of injured tissues. Eduardo Marban, Director of the Cedars-Sinai Smidt Heart Institute, emphasizes that TY1 offers the ability to repair the body without using stem cells and represents the first example of a new class of drugs called “exomers.”

TY1 possesses the structure of existing RNA drugs and functions like its natural counterpart. The drug’s primary function is to activate the TREX1 gene to boost the effectiveness of immune cells around damaged DNA, thereby ensuring the clearance of DNA damage and the repair of tissues. This process accelerates recovery by minimizing the damage that occurs especially after a heart attack.

Interestingly, TY1’s effect is not limited to heart tissue. Ibrahim states that by enhancing DNA repair, TY1 could potentially provide benefits in conditions where the body attacks its own healthy tissues, such as autoimmune diseases. This mechanism offers a completely new approach to tissue healing, paving the way for new treatment options for various diseases.

Following successful results in animal models, TY1 will undergo clinical trials in humans. If it performs as expected, this drug will open the doors to a new era in treating cellular damage caused by sudden events and chronic inflammation.

You Might Also Like;